Immix Biopharma (NASDAQ:IMMX) versus Pharming Group (NASDAQ:PHAR) Head to Head Comparison

Pharming Group (NASDAQ:PHAR) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Volatility and Risk

Pharming Group has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500.

Profitability

This table compares Pharming Group and Immix Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pharming Group	-2.19%	-3.31%	-1.78%
Immix Biopharma	N/A	-205.35%	-110.63%

Institutional and Insider Ownership

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 55.4% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Pharming Group and Immix Biopharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	1	1	3	0	2.40
Immix Biopharma	1	1	1	0	2.00

Pharming Group presently has a consensus target price of $30.00, indicating a potential upside of 95.06%. Immix Biopharma has a consensus target price of $8.00, indicating a potential upside of 257.14%. Given Immix Biopharma’s higher possible upside, analysts clearly believe Immix Biopharma is more favorable than Pharming Group.

Valuation and Earnings

This table compares Pharming Group and Immix Biopharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$297.20 million	3.55	-$11.84 million	($0.13)	-118.31
Immix Biopharma	N/A	N/A	-$21.61 million	($0.77)	-2.91

Pharming Group has higher revenue and earnings than Immix Biopharma. Pharming Group is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Pharming Group beats Immix Biopharma on 7 of the 13 factors compared between the two stocks.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

About Immix Biopharma

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.